Accelmed Partners Makes $35M Growth Investment in SKNV

November 14, 2022

Accelmed Partners completed a $35 million growth investment in SKNV Inc., a Florida-based dermatology digital health company and FDA-registered 503B outsourcing facility that supplies customized medications and an ecommerce/in-practice dispensing platform. Proceeds will fund a new manufacturing facility in Florida, scale SKNV's proprietary digital platform, expand its U.S. sales footprint, and add strategic management hires.

Buyers
Accelmed Partners
Targets
SKNV Inc.
Location
Florida, United States
Transaction Type
Growth capital

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.